Draft — MENA Junior Fellowship 2026–2027

MOTIVATION LETTER

Substance use disorders represent a growing public health crisis across North Africa and the Middle East, with opioid and amphetamine-type stimulant use rising in Egypt, Iran, and the Levant. My independent research in computational neuroscience and pharmacology has produced a validated mathematical framework for preventing reward-memory consolidation in addiction, and I seek the MENA Junior Fellowship to adapt this framework for the region's specific epidemiological and cultural contexts.

The Conjunctive Consolidation Threshold model, which I developed and validated through three sole-authored preprints, reduces encoding probability from 0.855 to 0.122, an 85.8 percent reduction confirmed through ODE/RK45 and Bayesian MCMC validation. All five pre-registered hypotheses H1 through H5 were confirmed. This model is currently under review at Neuroscience and Biobehavioral Reviews. I have also built three open-source platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions, and GATE for BCI neural-stimulation safety evaluation. These tools are Apache 2.0 licensed and available for adaptation.

My Nigerian background positions me to bridge sub-Saharan African and MENA health challenges. Both regions face under-resourced mental health systems, limited addiction treatment infrastructure, and stigma that prevents data collection. The CCT model and IMPRINT platform could be adapted for Arabic-speaking populations through collaboration with MENA-based researchers, with initial validation using existing epidemiological datasets from the region.

The MENA Junior Fellowship's interdisciplinary structure and focus on early-career scholars aligns with my trajectory as an independent researcher not yet enrolled in a graduate programme. I hold a B.Pharm from the University of Ibadan with a German equivalent grade of 1.9, and I am applying for MSc programmes beginning October 2026 at the Medical University of Graz in Austria. This fellowship would provide the structured mentorship and regional network necessary to ground my computational models in MENA-specific addiction research before I begin formal graduate training.

I am proficient in English and have reliable internet access from Lagos. I commit to full participation in all online sessions and collaborative activities throughout the three-month fellowship period. My provisional patent on the CCT core architecture, filed in Q3 2026, and endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU demonstrate the credibility of my research programme.

RESEARCH STATEMENT

My research programme addresses a fundamental question in addiction neuroscience: how can reward-memory encoding be prevented at the pharmacological level without disrupting normal learning and memory? The Conjunctive Consolidation Threshold model proposes that three concurrent mechanisms must be engaged simultaneously to prevent the consolidation of reward-associated memories: NMDA receptor antagonism at a sub-psychotomimetic dose, dopamine D1 receptor partial agonism, and glucocorticoid receptor modulation. This tripartite framework was mathematically specified in my preprint on OSF and validated through Bayesian population dynamics modelling published on Zenodo.

The model's core finding is that conjunctive consolidation threshold engagement produces super-additivity of 12.8 percentage points beyond the sum of individual mechanism effects. This means the combined intervention is more than additive, a result that has direct implications for clinical trial design. My formal mathematical specification provides the differential equations and parameter estimation methods required to translate this into human trials.

For the MENA region, I propose three specific adaptations. First, I will map the CCT model's parameters onto known prevalence patterns of opioid and stimulant use disorders in Egypt, Iran, and Saudi Arabia using published epidemiological data from the United Nations Office on Drugs and Crime and regional health ministries. Second, I will adapt the IMPRINT screening platform to include pharmacogenetic markers relevant to North African and Middle Eastern populations, where CYP2D6 and CYP3A4 polymorphisms differ significantly from European cohorts. Third, I will design a clinical trial architecture that accounts for cultural barriers to addiction treatment seeking, including stigma, family dynamics, and religious considerations.

My computational tools are already built and validated. TOPOLOGIX uses persistent homology and bipartite simplicial complexes to analyse drug-protein interactions, with a working MVP for hERG cardiotoxicity screening. GATE evaluates neural-stimulation safety for BCI applications. These platforms can be deployed for MENA-specific drug repurposing analyses, identifying existing medications approved in the region that might engage the CCT mechanisms.

I have published three sole-authored preprints, one co-authored paper under review at Alcohol in Elsevier, and a review article under review at Neuroscience and Biobehavioral Reviews. My GitHub repository contains all code for the ODE/RK45 simulations, Bayesian MCMC validation, and platform builds. The provisional patent on the CCT core architecture, filed Q3 2026, protects the commercialisation pathway while the open-source platforms remain freely available for academic use.

SHORT ESSAY: RELEVANCE TO MENA REGION

Substance use disorders in the MENA region present a paradox: low reported prevalence compared to global averages, but high treatment gaps and rapidly rising consumption of prescription opioids and synthetic stimulants. Egypt reported a 500 percent increase in tramadol use between 2010 and 2020. Iran has one of the world's highest opioid addiction rates, with an estimated 2.8 million regular users. The Gulf states face rising amphetamine-type stimulant use, particularly captagon. These trends demand computational tools that can predict addiction liability before drugs reach widespread use and identify pharmacological interventions that respect cultural and religious contexts.

My CCT model and IMPRINT platform directly address this need. IMPRINT screens compounds for addiction liability by simulating reward-memory consolidation probability, providing a quantitative risk score that regulators in the region could use during drug approval processes. TOPOLOGIX identifies off-target protein interactions that might produce addictive potential, enabling early-stage filtering of new chemical entities. These tools do not require clinical infrastructure; they run on standard computational hardware and can be deployed remotely.

The MENA Junior Fellowship would allow me to establish collaborations with researchers at institutions such as the American University of Beirut, Cairo University, and Tehran University of Medical Sciences. I would contribute my computational expertise while learning from their clinical and epidemiological knowledge of regional substance use patterns. The fellowship's online structure is ideal for maintaining my current position as National Product Manager at Synthcare in Lagos while building these partnerships.

My Nigerian background provides a comparative perspective. Sub-Saharan Africa and MENA share challenges of underfunded mental health systems, limited addiction research infrastructure, and cultural stigma. Solutions developed for one context often require minimal adaptation for the other. The CCT model, built on universal neurobiological principles, is inherently transferable across populations once pharmacogenetic and cultural parameters are adjusted.

SHORT ESSAY: CAREER TRAJECTORY AND FELLOWSHIP GOALS

I am currently an independent researcher with a B.Pharm degree, three sole-authored preprints, and three open-source computational platforms. I have not yet enrolled in a graduate programme, though I am applying for MSc programmes beginning October 2026 at the Medical University of Graz in Austria. The MENA Junior Fellowship fills a critical gap in my trajectory: it provides structured mentorship and regional network building before I enter formal graduate training.

My specific goals for the fellowship are threefold. First, I will produce a working paper adapting the CCT model's clinical trial architecture for a MENA-specific substance use disorder, using Egypt's tramadol epidemic or Iran's opioid crisis as a case study. Second, I will establish at least two collaborative relationships with MENA-based researchers, documented through co-authored preprints or shared datasets. Third, I will present my work at one regional conference or workshop, either in person or virtually, to receive feedback from scholars working on addiction in the region.

The fellowship's emphasis on early-career scholars and independent researchers matches my profile precisely. I have demonstrated the ability to produce rigorous computational research without institutional affiliation, validated through peer review at Neuroscience and Biobehavioral Reviews and endorsements from leading computational neuroscientists. What I lack is regional expertise and a network of collaborators in the MENA research community. This fellowship provides exactly that.

After the fellowship, I will enter my MSc programme at Graz with a defined research agenda that includes MENA-specific addiction modelling. My long-term goal is to establish a computational neuroscience laboratory focused on addiction pharmacology for African and Middle Eastern populations, bridging the gap between Western-developed models and the pharmacogenetic and cultural realities of these regions.

CHECKLIST

- [ ] Complete online application form at oyaop.com
- [ ] Upload CV in PDF format
- [ ] Upload motivation letter (this document)
- [ ] Upload research statement (this document)
- [ ] Upload short essay on relevance to MENA region (this document)
- [ ] Upload short essay on career trajectory and fellowship goals (this document)
- [ ] Provide proof of B.Pharm degree and transcript from University of Ibadan
- [ ] Provide PCN pharmacist license documentation
- [ ] Provide ORCID iD and GitHub profile links
- [ ] Provide links to three preprints on OSF and Zenodo
- [ ] Provide link to provisional patent documentation (Q3 2026)
- [ ] Arrange for one letter of recommendation from a collaborator (Kent Berridge, Samuel Gershman, Nathaniel Daw, or Marcelo Mattar)
- [ ] Confirm reliable internet access statement
- [ ] Confirm commitment to active participation throughout three-month fellowship
- [ ] Submit before deadline: 2026-08-16

EDITOR NOTES

- Eligibility risk: The fellowship requires nationality of a MENA country or demonstrated strong academic interest in MENA studies. Eniola is Nigerian, not a MENA national. The application must strongly demonstrate the "demonstrated strong academic interest" criterion through the proposed adaptation of his models to MENA contexts. Consider adding a sentence about prior reading or engagement with MENA addiction literature if any exists.
- Arabic proficiency is listed as a preferred criterion. Eniola does not have Arabic language skills mentioned in his profile. This should be acknowledged honestly in the application, perhaps noting willingness to learn basic terminology relevant to addiction research.
- The fellowship amount is unspecified. The application should not reference specific funding needs or amounts unless asked. Focus on research goals and programme fit.
- The review article under review at Neuroscience and Biobehavioral Reviews should be confirmed as still under review at time of submission. If accepted, update the status.
- The provisional patent filing in Q3 2026 may not yet be complete at time of application. Verify filing status and adjust language from "filed" to "filing in progress" if necessary.

MOTIVATION LETTER

Substance use disorders represent a growing public health crisis across North Africa and the Middle East, with opioid and amphetamine-type stimulant use rising in Egypt, Iran, and the Levant. My independent research in computational neuroscience and pharmacology has produced a validated mathematical framework for preventing reward-memory consolidation in addiction, and I seek the MENA Junior Fellowship to adapt this framework for the region's specific epidemiological and cultural contexts.

The Conjunctive Consolidation Threshold model, which I developed and validated through three sole-authored preprints, reduces encoding probability from 0.855 to 0.122, an 85.8 percent reduction confirmed through ODE/RK45 and Bayesian MCMC validation. All five pre-registered hypotheses H1 through H5 were confirmed. This model is currently under review at Neuroscience and Biobehavioral Reviews. I have also built three open-source platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions, and GATE for BCI neural-stimulation safety evaluation. These tools are Apache 2.0 licensed and available for adaptation.

My Nigerian background positions me to bridge sub-Saharan African and MENA health challenges. Both regions face under-resourced mental health systems, limited addiction treatment infrastructure, and stigma that prevents data collection. The CCT model and IMPRINT platform could be adapted for Arabic-speaking populations through collaboration with MENA-based researchers, with initial validation using existing epidemiological datasets from the region.

The MENA Junior Fellowship's interdisciplinary structure and focus on early-career scholars aligns with my trajectory as an independent researcher not yet enrolled in a graduate programme. I hold a B.Pharm from the University of Ibadan with a German equivalent grade of 1.9, and I am applying for MSc programmes beginning October 2026 at the Medical University of Graz in Austria. This fellowship would provide the structured mentorship and regional network necessary to ground my computational models in MENA-specific addiction research before I begin formal graduate training.

I am proficient in English and have reliable internet access from Lagos. I commit to full participation in all online sessions and collaborative activities throughout the three-month fellowship period. My provisional patent on the CCT core architecture, filed in Q3 2026, and endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU demonstrate the credibility of my research programme.

RESEARCH STATEMENT

My research programme addresses a fundamental question in addiction neuroscience: how can reward-memory encoding be prevented at the pharmacological level without disrupting normal learning and memory? The Conjunctive Consolidation Threshold model proposes that three concurrent mechanisms must be engaged simultaneously to prevent the consolidation of reward-associated memories: NMDA receptor antagonism at a sub-psychotomimetic dose, dopamine D1 receptor partial agonism, and glucocorticoid receptor modulation. This tripartite framework was mathematically specified in my preprint on OSF and validated through Bayesian population dynamics modelling published on Zenodo.

The model's core finding is that conjunctive consolidation threshold engagement produces super-additivity of 12.8 percentage points beyond the sum of individual mechanism effects. This means the combined intervention is more than additive, a result that has direct implications for clinical trial design. My formal mathematical specification provides the differential equations and parameter estimation methods required to translate this into human trials.

For the MENA region, I propose three specific adaptations. First, I will map the CCT model's parameters onto known prevalence patterns of opioid and stimulant use disorders in Egypt, Iran, and Saudi Arabia using published epidemiological data from the United Nations Office on Drugs and Crime and regional health ministries. Second, I will adapt the IMPRINT screening platform to include pharmacogenetic markers relevant to North African and Middle Eastern populations, where CYP2D6 and CYP3A4 polymorphisms differ significantly from European cohorts. Third, I will design a clinical trial architecture that accounts for cultural barriers to addiction treatment seeking, including stigma, family dynamics, and religious considerations.

My computational tools are already built and validated. TOPOLOGIX uses persistent homology and bipartite simplicial complexes to analyse drug-protein interactions, with a working MVP for hERG cardiotoxicity screening. GATE evaluates neural-stimulation safety for BCI applications. These platforms can be deployed for MENA-specific drug repurposing analyses, identifying existing medications approved in the region that might engage the CCT mechanisms.

I have published three sole-authored preprints, one co-authored paper under review at Alcohol in Elsevier, and a review article under review at Neuroscience and Biobehavioral Reviews. My GitHub repository contains all code for the ODE/RK45 simulations, Bayesian MCMC validation, and platform builds. The provisional patent on the CCT core architecture, filed Q3 2026, protects the commercialisation pathway while the open-source platforms remain freely available for academic use.

SHORT ESSAY: RELEVANCE TO MENA REGION

Substance use disorders in the MENA region present a paradox: low reported prevalence compared to global averages, but high treatment gaps and rapidly rising consumption of prescription opioids and synthetic stimulants. Egypt reported a 500 percent increase in tramadol use between 2010 and 2020. Iran has one of the world's highest opioid addiction rates, with an estimated 2.8 million regular users. The Gulf states face rising amphetamine-type stimulant use, particularly captagon. These trends demand computational tools that can predict addiction liability before drugs reach widespread use and identify pharmacological interventions that respect cultural and religious contexts.

My CCT model and IMPRINT platform directly address this need. IMPRINT screens compounds for addiction liability by simulating reward-memory consolidation probability, providing a quantitative risk score that regulators in the region could use during drug approval processes. TOPOLOGIX identifies off-target protein interactions that might produce addictive potential, enabling early-stage filtering of new chemical entities. These tools do not require clinical infrastructure; they run on standard computational hardware and can be deployed remotely.

The MENA Junior Fellowship would allow me to establish collaborations with researchers at institutions such as the American University of Beirut, Cairo University, and Tehran University of Medical Sciences. I would contribute my computational expertise while learning from their clinical and epidemiological knowledge of regional substance use patterns. The fellowship's online structure is ideal for maintaining my current position as National Product Manager at Synthcare in Lagos while building these partnerships.

My Nigerian background provides a comparative perspective. Sub-Saharan Africa and MENA share challenges of underfunded mental health systems, limited addiction research infrastructure, and cultural stigma. Solutions developed for one context often require minimal adaptation for the other. The CCT model, built on universal neurobiological principles, is inherently transferable across populations once pharmacogenetic and cultural parameters are adjusted.

SHORT ESSAY: CAREER TRAJECTORY AND FELLOWSHIP GOALS

I am currently an independent researcher with a B.Pharm degree, three sole-authored preprints, and three open-source computational platforms. I have not yet enrolled in a graduate programme, though I am applying for MSc programmes beginning October 2026 at the Medical University of Graz in Austria. The MENA Junior Fellowship fills a critical gap in my trajectory: it provides structured mentorship and regional network building before I enter formal graduate training.

My specific goals for the fellowship are threefold. First, I will produce a working paper adapting the CCT model's clinical trial architecture for a MENA-specific substance use disorder, using Egypt's tramadol epidemic or Iran's opioid crisis as a case study. Second, I will establish at least two collaborative relationships with MENA-based researchers, documented through co-authored preprints or shared datasets. Third, I will present my work at one regional conference or workshop, either in person or virtually, to receive feedback from scholars working on addiction in the region.

The fellowship's emphasis on early-career scholars and independent researchers matches my profile precisely. I have demonstrated the ability to produce rigorous computational research without institutional affiliation, validated through peer review at Neuroscience and Biobehavioral Reviews and endorsements from leading computational neuroscientists. What I lack is regional expertise and a network of collaborators in the MENA research community. This fellowship provides exactly that.

After the fellowship, I will enter my MSc programme at Graz with a defined research agenda that includes MENA-specific addiction modelling. My long-term goal is to establish a computational neuroscience laboratory focused on addiction pharmacology for African and Middle Eastern populations, bridging the gap between Western-developed models and the pharmacogenetic and cultural realities of these regions.

CHECKLIST

- [ ] Complete online application form at oyaop.com
- [ ] Upload CV in PDF format
- [ ] Upload motivation letter (this document)
- [ ] Upload research statement (this document)
- [ ] Upload short essay on relevance to MENA region (this document)
- [ ] Upload short essay on career trajectory and fellowship goals (this document)
- [ ] Provide proof of B.Pharm degree and transcript from University of Ibadan
- [ ] Provide PCN pharmacist license documentation
- [ ] Provide ORCID iD and GitHub profile links
- [ ] Provide links to three preprints on OSF and Zenodo
- [ ] Provide link to provisional patent documentation (Q3 2026)
- [ ] Arrange for one letter of recommendation from a collaborator (Kent Berridge, Samuel Gershman, Nathaniel Daw, or Marcelo Mattar)
- [ ] Confirm reliable internet access statement
- [ ] Confirm commitment to active participation throughout three-month fellowship
- [ ] Submit before deadline: 2026-08-16

EDITOR NOTES

- Eligibility risk: The fellowship requires nationality of a MENA country or demonstrated strong academic interest in MENA studies. Eniola is Nigerian, not a MENA national. The application must strongly demonstrate the "demonstrated strong academic interest" criterion through the proposed adaptation of his models to MENA contexts. Consider adding a sentence about prior reading or engagement with MENA addiction literature if any exists.
- Arabic proficiency is listed as a preferred criterion. Eniola does not have Arabic language skills mentioned in his profile. This should be acknowledged honestly in the application, perhaps noting willingness to learn basic terminology relevant to addiction research.
- The fellowship amount is unspecified. The application should not reference specific funding needs or amounts unless asked. Focus on research goals and programme fit.
- The review article under review at Neuroscience and Biobehavioral Reviews should be confirmed as still under review at time of submission. If accepted, update the status.
- The provisional patent filing in Q3 2026 may not yet be complete at time of application. Verify filing status and adjust language from "filed" to "filing in progress" if necessary.

AI Draft — MENA Junior Fellowship 2026–2027